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Abstract
Background: Anti-obesity drugs are widely used to prevent the complications of obesity, however, the effects of anti-
obesity drugs on cardiovascular risk factors are unclear at the present time. We carried out a comprehensively systematic
review and meta-analysis to assess the effects of anti-obesity drugs on cardiovascular risk factors.
Methodology and Principal Findings: We systematically searched Medline, EmBase, the Cochrane Central Register of
Controlled Trials, reference lists of articles and proceedings of major meetings for relevant literatures. We included
randomized placebo-controlled trials that reported the effects of anti-obesity drugs on cardiovascular risk factors compared
to placebo. Overall, orlistat produced a reduction of 2.39 kg (95%CI-3.34 to 21.45) for weight, a reduction of 0.27 mmol/L
(95%CI: 20.36 to 20.17) for total cholesterol, a reduction of 0.21 mmol/L (95%CI: 20.30 to 20.12) for LDL, a reduction of
0.12 mmol/L (95%CI: 20.20 to 20.04) for fasting glucose, 1.85 mmHg reduction (95%CI: 23.30 to 20.40) for SBP, and a
reduction of 1.49 mmHg (95%CI: 22.39 to 20.58) for DBP. Sibutramine only showed effects on weight loss and triglycerides
reduction with statistical significances. Rimonabant was associated with statistically significant effects on weight loss, SBP
reduction and DBP reduction. No other significantly different effects were identified between anti-obesity therapy and
placebo.
Conclusion/Significance: We identified that anti-obesity therapy was associated with a decrease of weight regardless of the
type of the drug. Orlistat and rimonabant could lead to an improvement on cardiovascular risk factors. However,
Sibutramine may have a direct effect on cardiovascular risk factors.
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Introduction
Cardiovascular disease is the leading cause of premature
morbidity and mortality worldwide for both men and women
[1–4]. Obesity and overweight are escalating and raising
considerable public concern because they increase the prevalence
of severe cardiovascular events and other systemic diseases,
causing great costs and burden to both society and families [5–
7]. Over the past few decades, several randomized controlled trials
have already indicated that reduction in weight could reduce the
risk of cardiovascular outcomes and other systemic diseases. In
practice, lifestyle modifications remain the primary approach for
obesity therapy. However, lifestyle modifications have their own
limitation on lasting weight loss, especially for adolescent obesity.
In fact, more than 80% of the highly motivated patients are unable
to achieve weight loss with dietary and lifestyle modifications
alone. Lifestyle modifications are not sufficient impact on weight
loss and attentions have been drawn to additional effective
prevention therapies [7–12]. Anti-obesity drugs represent addi-
tional effective therapies which have clear effect on weight loss.
However, the effects of anti-obesity drugs on cardiovascular risk
factors remain unclear [7,13]. Previous review [14] only provided
evidence that anti-obesity drugs have a role in weight loss for obese
adolescents, but did not provide clear evidence showing whether
anti-obesity therapy was associated with effects on cardiovascular
risk factors.
Recently, several randomized controlled trials [15,16] investi-
gating the use of anti-obesity therapy have been performed. Data
from these recent trials are needed to be evaluated to formulate a
conclusion regarding the efficacy of anti-obesity therapy. We
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e39062therefore conducted a systematic review and meta-analysis of
pooled data from randomized controlled trials, including the latest
evidence of the association between anti-obesity therapy and the
risk of cardiovascular risk factors and any possible adverse
reactions.
Methods
Data Sources, Search Strategy and Selection Criteria
Randomized controlled trials and literature reporting trials of
anti-obesity therapy in English met the eligibility criteria for our
meta-analysis regardless of publication status (published, unpub-
lished, in press or in progress), and relevant literatures were found
by the following procedures:
(1) Electronic searches: We searched the electronic databases
EmBase, Medline, and the Cochrane Center Register of
Controlled Trials for articles to a time limit of September 20,
2010, using ‘‘rimonabant’’, ‘‘sibutramine’’, ‘‘orlistat’’, ‘‘obesity’’
and ‘‘randomized controlled trial’’ as the search terms. All
reference lists from reports on non-randomized controlled trials
were searched manually for additional eligible studies.
(2) Other source: We contacted the authors to obtain any
possible additional published or unpublished data and searched
the proceedings of annual meetings in the Cochrane Obesity
Group Specialized Register. In addition, we searched the ongoing
randomized controlled trials, which had been registered as been
completed but not yet been published, in the metaRegister of
Controlled Trials. Medical subject headings and methods, patient
population and intervention were used to identify relevant trials.
This review was conducted and reported according to the
PRISMA (Preferred Reporting Items for Systematic Reviews
and Meta-Analysis) Statement issued in 2009 (Checklist S1) [17].
The literature search, data extraction, and quality assessment
were undertaken independently by two authors (Xiu-Qiang Ma
and Jian Lu) with a standardized approach, and any disagreement
between these two authors was settled by a third author (Yu-Hao.
Zhou) until a consensus was reached.
All completed randomized controlled trials assessing the effects
of anti-obesity therapy with placebo as control and reporting at
least one outcome of cardiovascular risk factors were included as
eligible trials.
Data Collection and Quality Assessment
One author (Yu-Hao. Zhou) designed a standard data
extraction procedure, and then three authors (Cheng Wu, Jia
Guo, Xiao-Fei Ye) checked each full-text trial for eligibility and
extracted and tabulated all relevant data with a standardized flow
path. Extracted data included patients’ baseline characteristics, the
type and dose of anti-obesity drugs, follow-up duration, change in
weight, cardiovascular risk factors, and any possible adverse
outcomes. Disagreements regarding the data were settled by group
discussion.
Study quality was assessed using the Jadad [18] scores (Jin-Fang
Xu, Yu-Hao Zhou) based on randomization, concealment of the
treatment allocation, blinding, completeness of follow-up, and the
use of intention-to-treat analysis.
Statistical Analysis
Relative risks (RRs) or mean differences (MDs) with 95%
confidence intervals (CIs) were calculated using outcomes
extracted from each trial before data pooling. We used RRs
with 95% CIs for binary data to estimate the effects of anti-
obesity drugs on adverse events and MDs with 95% CIs for
continuous data to estimate the effects of anti-obesity drugs on
weight loss, and cardiovascular risk factors, such as total
cholesterol, LDL, HDL, triglycerides, fasting glucose, SBP and
DBP. In order to explore potential heterogeneity in estimates of
treatment effect, we performed univariate meta-regression and
compared summary results from subgroup analysis based on the
type of anti-obesity drug, mean age, follow-up years, and study
quality. We chose the random-effects model [19] with Mantel-
Haenszel Statistics for all estimates of effect. Heterogeneity of
treatment effects between studies was investigated visually by
funnel plot and statistically by the heterogeneity I
2 statistic. I
2
statistic of 0%–40% indicates unimportant heterogeneity, 30%–
60% indicates moderate heterogeneity, 50%–90% indicates
substantial heterogeneity, and 75%–100% indicates considerable
heterogeneity [20]. All reported P values were two-side and p
values less than 0.05 were regarded as significant for all included
studies. All analyses were carried out using STATA (version
10.0).
Results
We identified 957 potential articles from our initial electronic
search, and 826 were excluded after a preliminary review of
searches. The remaining 131 studies were retrieved for detailed
assessment and 21 randomized controlled trials [15,16,21–39] met
our inclusion criteria (Figure 1 and Protocol S1). The 21 trials
provided data of 13759 people with obesity (mean: 655 people,
range: 46 to 3277 people). Table 1 summarizes the baseline
Figure 1. Flow diagram of the literature search and trials
selection process.
doi:10.1371/journal.pone.0039062.g001
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PLoS ONE | www.plosone.org 3 June 2012 | Volume 7 | Issue 6 | e39062characteristics of the included studies and their participants. The
follow-up for patients ranged from 4 to 48 months, with a mean of
14.7 months. Among these included trials, 10 studies evaluated
orlistat therapy [21–25,28,30,32–34], 3 [16,37,38] evaluated
rimonabant therapy and remaining 8 [15,26,27,29,31,35,36,39]
evaluated sibutramine therapy. Because the included trials scarcely
reported on the key indicators of trial quality, we assessed the
quality of the trials by the pre-fixed criteria using the Jadad score.
Overall, five trials scored 6, seven scored 5, six scored 4, two
scored 3 and the remaining one scored 2.
Data for the effect of anti-obesity drugs on weight loss compared
with placebo were available from 16 trials (Figure 2). Overall, we
noted that with anti-obesity therapy, weight was significantly
reduced by 3.13 kg (95%CI: 24.00 to 22.26) compared with
placebo. Furthermore, orlistat, sibutramine, and rimonabant
produced reductions of 2.39 kg (95%CI: 23.34 to 21.45),
3.73 kg (95%CI: 26.00 to 21.46), and 3.66 kg (95%CI: 24.17
to 23.15) in weight, respectively.
Data for the effects of anti-obesity therapy on cardiovascular
risk factors were divided into seven classes, i.e., total cholesterol,
LDL, HDL, triglycerides, fasting glucose, SBP and DBP
(Figure 3). Overall, orlistat therapy resulted in a reduction of
0.27 mmol/L (95%CI: 20.36 to 20.17) in total cholesterol, a
reduction of 0.21 mmol/L (95%CI: 20.30 to 20.12) in LDL, a
reduction of 0.12 mmol/L (95%CI: 20.20 to 20.04) in fasting
glucose, a reduction of 1.85 mmHg (95%CI: 23.30 to 20.40) in
SBP, and a reduction of 1.49 mmHg (95%CI: 22.39 to 20.58)
in DBP. Moreover, sibutramine showed an effect on weight loss
(MD=23.73 kg, 95%CI: 26.00 to 21.46), triglycerides reduc-
tion (MD=20.13 mmol/L, 95%CI: 20.26 to 20.00) with a
statistical significance. Rimonabant showed clear effects on
weight loss (MD=23.66 kg, 95%CI: 24.17 to 23.15), SBP
reduction (MD=21.63 mmHg, 95%CI: 22.76 to 20.51), and
DBP reduction (MD=21.60 mmHg, 95%CI: 22.80 to 20.39).
We also noted that some adverse outcomes were reported in
several trials and 12 trials reported data for total adverse event.
Overall, anti-obesity therapy increased the risk of drug-related
adverse events by 8% when compared with placebo (RR: 1.08,
95%CI: 1.02 to 1.14, Figure 4). Similarly, anti-obesity therapy also
resulted in a increase of 73% in the risk of gastrointestinal diseases
(RR: 1.73, 95%CI: 1.40 to 2.15), 86% in the risk of hypertension
(RR: 1.86, 95%CI: 1.28 to 2.71), 195% in the risk of tachycardia
(RR: 2.95, 95%CI: 1.56 to 5.58), and 371% in the risk of dry
mouth (RR: 4.71, 95%CI: 1.63 to 13.65). Anti-obesity therapy did
not have an effect on infections and infestations, headache, rash,
abdominal pain, upper respiratory tract infection, influenza and
pharyngitis.
We observed evidence of heterogeneity in the magnitude of the
effect across the included trials for weight loss, HDL and
Triglycerides. However, we performed a sequential exclusion of
each trial from the pooled analysis and these exclusions did not
affect our conclusions. Therefore, we did subgroup analyses to
minimize the consequences of heterogeneity among the included
trials based on mean age, follow-up years, and study quality
(Table 2). Subgroup analyses were performed for weight loss,
HDL and Triglycerides. The outcomes showed that there was
evidence of heterogeneity in the magnitude of the effect across the
included trials. The subgroup analysis based on the type of anti-
obesity drugs contributed to the minimization of heterogeneity.
However, few subsets provided a unanimous conclusion, and this
might be due to the fact that fewer trials were included in these
subsets.
Figure 2. Mean reduction in weight loss (kg) based on sibutramine and orlistat. CI, confidence intervals; IV, inverse variance.
doi:10.1371/journal.pone.0039062.g002
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Obesity remains the most frequent cause of cardiovascular
disease, stroke, type 2 diabetes mellitus and other systemic diseases
[40]. Evidence from several studies shows that obesity shortens life
range from 4.8 to 7.1 years for people over forty years old, and it is
associated with a tremendous social burden [41,42]. Although
many anti-obesity drugs show strong effects on weight loss, some
researches [15,43] indicate that the effects of anti-obesity drugs on
the risk of cardiovascular risk factors remain unclear.
The results of this meta-analysis showed that anti-obesity
therapy significantly reduced weight, total cholesterol, LDL and
fasting glucose, and increased the risk of total adverse event,
tachycardia, gastrointestinal diseases, hypertension, and dry
mouth.
Due to the fact that the cardiovascular risk factors were
increased in patients with diabetes mellitus, hyperlipidaemia,
hyperglycemia, and hypertension [44,45], we therefore restricted
inclusion criteria to ensure our study to explore the effects of anti-
obesity drugs on cardiovascular risk factors.
The participants in individual studies included in our meta-
analysis could correspond with our eligible criteria. Patients with
cardiovascular diseases or other cardiovascular risk factors should
be excluded. Furthermore, the patients with uncontrolled hyper-
tension, more than 4 kg weight loss in 3 months, surgery for
weight reduction, a history of post surgical adhesions, bulimia or
Figure 3. Subgroup analyses for the effects of anti-obesity on cardiovascular risk factors based on the type of drug. CI, confidence
intervals; IV, inverse variance.
doi:10.1371/journal.pone.0039062.g003
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PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e39062Figure 4. Summary of the relative risks of all adverse outcomes assessed.
doi:10.1371/journal.pone.0039062.g004
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PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e39062Table 2. Subgroup analysis of weight loss, HDL and Triglycerides after treatment with anti-obesity agents.
Subgroup
MD
(95% CI) P value
P value for
heterogeneity
Weight loss Orlistat Mean age .45 21.17 [ 21.75, 20.58] ,0.001 0.86
18–45 23.06 [23.92, 22.19] ,0.001 0.89
,18 2 ––
Follow-up (month) .12 22.80 [23.46, -2.14] ,0.001 0.44
,12 21.15 [21.77, 20.53] ,0.001 –
Jadad score .4 22.20 [23.57, 20.84] 0.002 0.01
,4 22.66 [23.86, 21.47] ,0.001 0.16
Sibutramine Mean age .45 20.10 [20.78, 0.58] 0.77 –
18–45 23.89 [24.92, 22.86] ,0.001 0.83
,18 25.37 [28.20, 22.54] ,0.001 0.06
Follow-up (month) .12 22.80 [25.48, 20.11] 0.04 ,0.01
,12 25.07 [27.93, 22.21] ,0.001 0.02
Jadad score .5 22.80 [25.15, 20.45] 0.02 ,0.01
,5 25.80 [29.61, 21.99] 0.003 0.008
Rimonabant Mean age .45 23.66 [24.17, 23.15] ,0.001 0.26
18–45 – – –
,18 – – –
Follow-up (month) .12 23.66 [24.17, 23.15] ,0.001 0.26
,12 – – –
Jadad score .5 23.67 [24.55, 22.79] ,0.001 0.10
,5 23.60 [24.36, 22.84] ,0.001 –
HDL Orlistat Mean age .45 20.04 [20.23, 0.15] 0.69 –
18–45 20.02 [20.04, 0.01] 0.16 0.37
,18 – – –
Follow-up (month) .12 20.02 [20.04, 0.00] 0.09 0.63
,12 – – –
Jadad score .4 20.01 [20.04, 0.01] 0.25 0.40
,4 20.05 [20.11, 0.01] 0.09 0.83
Sibutramine Mean age .45 0.00 [20.04, 0.04] 1.00 –
18–45 0.08 [0.00, 0.15] 0.04 0.20
,18 – – –
Follow-up (month) .12 0.04 [20.02, 0.11] 0.16 0.05
,12 – – –
Jadad score .5 0.02 [20.03, 0.07] 0.43 0.16
,5 0.13 [0.02, 0.24] 0.02 –
Rimonabant Mean age .45 0.13 [20.04, 0.31] 0.14 ,0.001
18–45 – – –
,18 – – –
Follow-up (month) .12 0.13 [20.04, 0.31] 0.14 ,0.001
,12 – – –
Jadad score .5 3.61 [23.47, 10.68] 0.32 ,0.001
,5 0.09 [0.06, 0.12] ,0.001 –
Triglycerides Orlistat Mean age .45 20.12 [20.30, 0.06] 0.19 –
18–45 0.08 [20.20, 0.36] 0.58 0.006
,18 – – –
Follow-up (month) .12 20.00 [20.16, 0.15] 0.95 0.01
,12 – – –
Jadad score .4 20.06 [20.16, 0.05] 0.27 0.96
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plasma lipids in the month before study entry, and drug or alcohol
abuse did not meet our inclusion criteria either [15,21–34].
Recently, several randomized controlled trials [41,43,46]
indicated that anti-obesity therapy had direct effects on weight
loss and cardiovascular risk factors in obese individuals. Further-
more, Daniels’s study [15] indicated that sibutramine might have
some direct cardiovascular effects on obese adolescents, although
they concluded that no evidence showed sibutramine produced an
increase in the risk of cardiovascular risk factors, and the reason
could be that cardiovascular risk factors might be affected by
reduction in weight. Therefore, we restricted the baseline
characteristics of obese individuals between these two groups to
explore the correlation between anti-obesity drugs and cardiovas-
cular risk factors.
Previous researches [45,47] reported that anti-obesity drugs
could reduce the body weight, contributing to an improvement in
cardiovascular risk factors. However, the direct effect of anti-
obesity drugs on cardiovascular risk factors is unclear. Further-
more, obesity usually accompanies with comorbidities, especially
for older obese individuals. We therefore performed a systematic
review and meta-analysis to assess intrinsic correlation between
anti-obesity therapies and cardiovascular risk factors.
Previous meta-analysis [14] only demonstrated the effect of anti-
obesity therapy on cardiovascular risk factors in adolescents, and
provided weak correlation between them. However, this meta-
analysis showed that anti-obesity therapy could reduce some
cardiovascular risk factors, such as total cholesterol, LDL and
fasting glucose, but had no effect on triglycerides, SBP and DBP.
Orlistat may play an important role in reducing SBP, DBP, total
cholesterol, LDL and fasting glucose. The effect of orlistat on
cardiovascular risk factors seems to be weak, although reduction in
several cardiovascular risk factors was reported. However, the
reason for this significant difference may arise from weight loss.
Therefore, the reason for orlistat being superior to sibutramine
could be that orlistat belongs to a class of anti-obesity agents that
act directly and specifically at the site of fat breakdown in the
lumen of the stomach and small intestine, so the effect of arlistat on
cardiovascular risk factors seems to be weak [22].
Sibutramine produced an increase in several cardiovascular risk
factors. Interpretation of this result is that receiving sibutramine
includes the recognized effect of increased blood pressure, which
increased the risk of cardiovascular events, especially for high risk
people with previous cardiovascular disease [7]. Our research
showed that hypertension in drug-related adverse event was also
consistently higher in the sibutramine group than in the placebo
group, which might have a direct effect on cardiovascular risk
factors and contribute increase incidence of major cardiovascular
events.
Rimonabant as a new drug, which is commonly used for obese
people, produced a significant reduction in body weight.
Moreover, it could effectively reduce SBP and DBP. Previous
research [38] indicated that rimonabant therapy produced a
substantial mobilization of abdominal fat, which would predict an
improved cardiovascular risk profile. Rimonabant therapy alone
will not eradicate the epidemic of obesity, however, our study
provided evidence that rimonabant as a new approach could
reduce the body weight and the cardiovascular risk.
Neither HDL nor Triglycerides was impacted by obesity
medications, which might be due to the fact that the intrinsic
effect might be lessened or balanced by other different anti-obesity
drugs. For rimonabant therapy, it might produce an increase in
HDL significantly, and the reason could be that only limited trials
provided regarding data. For orslitat or sibutramine, it might have
no direct effect on HDL or triglycerides.
The limitations of our research are shown as follows: (i) Inherent
assumptions made by any meta-analysis–the analysis used pooled
data either published or provided by individual study authors, and
individual patient data or original data were unavailable, which
restricted us from performing more detailed relevant analysis and
obtaining more comprehensive results. (ii) The duration of follow-
up and drug dose could affect our conclusions about the
association between anti-obesity and cardiovascular risk factors.
(iii) We did not have sufficient or appropriate data to explore
detailed effects of anti-obesity therapy on body mass index, waist
Table 2. Cont.
Subgroup
MD
(95% CI) P value
P value for
heterogeneity
,4 0.03 [20.24, 0.31] 0.81 0.003
Sibutramine Mean age .45 20.06 [20.19, 0.07] 0.38 –
18–45 20.24 [20.43, 20.05] 0.01 0.72
,18 – – –
Follow-up (month) .12 20.13 [20.26, 20.00] 0.05 0.30
,12 – – –
Jadad score .5 20.11 [20.30, 0.08] 0.26 0.25
,5 20.22 [20.44, 20.00] 0.05 –
Rimonabant Mean age .45 20.11 [20.63, 0.42] 0.69 ,0.001
18–45 – – –
,18 – – –
Follow-up (month) .12 20.11 [20.63, 0.42] 0.69 ,0.001
,12 – – –
Jadad score .5 5.45 [25.89, 16.78] 0.35 ,0.001
,5 20.41 [20.56, 20.26] ,0.001 –
doi:10.1371/journal.pone.0039062.t002
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have low fat, low calorie, and AHA-type diet, which might play an
important role in influencing cardiovascular risk factors.
Therefore, in future research, it is important to focus on patients
with cardiovascular risk factors for primary prevention of
cardiovascular disease, and to combine other anti-obesity drugs
to provide an optimal therapy that minimizes adverse effects in
obese individuals. We suggest that the ongoing trials should be
improved in the following ways: (i) The adverse effects in clinical
trials should be recorded and reported normatively, so that the
side-effects of any treatment can be evaluated in future trials. (ii)
The role of different drugs, dosages and treatment durations
should be investigated in more detail to explore optimal anti-
obesity drug, dose and duration of treatment [48]. (iii) Weight loss,
body mass index and waist circumference should be recorded in
detail to provide comprehensive information in the future trials.
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